First patient in UK gets dose of jab designed to kill most common form of lung cancer – and stop it coming back

Doctors have begun trialling the world’s first mRNA lung cancer vaccine in patients, as experts hailed its “groundbreaking” potential to save thousands of lives.

Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8m deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor.

Now experts are testing a new jab that instructs the body to hunt down and kill cancer cells – then prevents them ever coming back. Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.

The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey.

  • BossDj@lemm.eeEnglish
    3317·
    3 months ago

    My cousin’s friend’s wife got the vaccine, and a month later had an STD even though neither of them had an STD before. Now my cousin has the same STD too because the government is spreading the vaccine through the air now.